Search Results for keywords:"Drug Enforcement Administration"

The Drug Enforcement Administration (DEA) has decided to revoke William Needham's Certificate of Registration to handle controlled substances in Mississippi. This decision was made because Needham is no longer authorized to practice nursing in Mississippi after his nursing licenses were revoked. The DEA issued an Order to Show Cause, but Needham did not respond, which led to a default judgment against him. Consequently, without a state license, he cannot legally dispense controlled substances and will not have his DEA registration or any related applications renewed.

Patheon API Manufacturing, Inc. has applied to the Drug Enforcement Administration (DEA) to become a registered bulk manufacturer of certain controlled substances. The company intends to produce these substances as Active Pharmaceutical Ingredients (APIs) for its customers, specifically focusing on synthetic tetrahydrocannabinols. The public, including existing manufacturers and applicants, may submit comments or request a hearing on this application by April 20, 2021.

The Stepan Company has applied to the Drug Enforcement Administration (DEA) to be registered as an importer of certain controlled substances, as per the notice from the Justice Department's DEA. The application is to import these substances to manufacture other controlled substances, but not for commercial sale in finished form. Interested parties, such as current manufacturers or applicants, can comment or request a hearing about this application until April 9, 2025. Comments and hearing requests should be submitted through specified DEA addresses or electronically via the Federal eRulemaking Portal.

The Drug Enforcement Administration (DEA) and the Department of Health and Human Services (HHS) have decided to delay the start date for two rules about using telemedicine to prescribe certain medications to December 31, 2025. These rules include the "Expansion of Buprenorphine Treatment via Telemedicine Encounter," which allows practitioners to prescribe medications for opioid use disorder, and "Continuity of Care via Telemedicine for Veterans Affairs Patients," which permits Veterans Affairs practitioners to prescribe controlled substances via telemedicine under specific conditions. The delay grants additional time to address any questions or issues and follows public feedback, with some comments favoring an immediate start and others requesting a postponement.

Stepan Company has applied to the Drug Enforcement Administration (DEA) to become a bulk manufacturer of certain controlled substances. This request was made on January 31, 2025, and is currently open for public comment until June 17, 2025. Individuals who are already registered manufacturers of these substances or are applicants for such a registration can submit their comments or objections electronically through the Federal eRulemaking Portal. Interested parties may also request a hearing on this application before the deadline if desired.

The Drug Enforcement Administration (DEA) issued an order to revoke Maria Dewitt's registration to handle controlled substances because she lacks the necessary authorization in Texas. Dewitt did not have a required prescriptive authority delegation agreement with a physician, which is essential for an advanced practice registered nurse in Texas to manage controlled substances. The administrative law judge upheld this decision, noting that without state authorization, Dewitt could not maintain her DEA registration. Consequently, her registration was revoked, and any further applications for registration in Texas were denied.

Patheon API Inc. has applied to the Drug Enforcement Administration to register as a bulk manufacturer of several controlled substances. The registration would allow the company to import these substances as reference standards for research and development in its API Manufacturing operations. Interested parties, including current registered bulk manufacturers, can submit comments or objections electronically by April 21, 2025, and may also request a hearing on the application by the same date. Comments submitted will be tracked, and successful submissions will receive a Comment Tracking Number.

Organix, Inc. has applied to the Drug Enforcement Administration (DEA) to become a registered producer of certain controlled substances, specifically synthetic versions of Marihuana and Tetrahydrocannabinol. The notice invites comments or objections from existing registered manufacturers and applicants by March 15, 2021. Requests for a hearing on the application must also be submitted by this date. Written feedback should be directed to the DEA in Springfield, Virginia.

Patheon Pharmaceuticals Inc. has applied to the Drug Enforcement Administration to become a registered bulk manufacturer of certain controlled substances. The company plans to use these substances as Active Pharmaceutical Ingredients in FDA-approved medications. Anybody interested can submit comments or objections electronically by May 12, 2025, through the Federal eRulemaking Portal. Requests for a hearing regarding this application are also due by the same date.

Scottsdale Research Institute has applied to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of certain controlled substances. This registration will allow them to manufacture these substances for internal research and analytical development purposes only. Comments or objections regarding this application can be submitted electronically until April 21, 2025, via the Federal eRulemaking Portal. A hearing request can also be made by the same date.